PDCL3P4

Across TCGA pan-cancer cohorts, PDCL3P4 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PDCL3P4 data layer compared with 20 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher PDCL3P4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PDCL3P4 expression acts as an unfavorable survival marker.

LUSC, LIHC, and SKCM are the cancer types where PDCL3P4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	II,III,IV	0.140	0.743	.001	30	view →
LIHC	DFS	Median	All	0.076	0.553	.002	24	view →
SKCM	DFS	Median	All	0.273	0.621	.017	10	view →
LUAD	DFS	Median	All	0.049	0.814	<.001	6	view →
SARC	DFS	Median	All	0.204	0.612	.046	3	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PDCL3P4–LUSC (OS)

Open the LUSC breakdown →